Long-term clinical outcomes, health-related quality of life, and costs in different treatment modalities of stable coronary artery disease

  • Harriet Stenvall, Ilkka Tierala, Pirjo Räsänen, Mika Laine, Harri Sintonen, Risto P. Roine
  • European Heart Journal - Quality of Care and Clinical Outcomes, May 2016, Oxford University Press (OUP)
  • DOI: 10.1093/ehjqcco/qcw024

Outcomes, quality of life, and costs of different treatment modalities of coronary artery disease.

What is it about?

In the transition towards value based health care there is a growing interest in health gains of treatment assessed by patient reported outcomes (PROs) such as health related quality of life (HRQoL). Our study showed no statistically significant differences between the patient groups in 8-year survival or change in HRQoL among survivors. The 8-year mean secondary care costs of CABG were over two-fold and almost four-fold, even after adjustment for baseline characteristics, compared with those of PCI and MT.

Why is it important?

Patient involvement and conduction of observational trials in routine care can make information on quality and treatment outcomes more accessible for patients as end users.


MD Harriet Stenvall
Helsingin Yliopisto

Considering the ongoing social and health care reform in Finland there is a demand for quality of care and clinical outcomes research. This takes engagement of stakeholders, co-operation between hospital districts and willingness to share information, including cost and patient safety data, for research purposes. Involving patient´s in their care by building in collection of PROs in routine care can help improve quality of care and identify patient groups who benefit the most from treatment.

Read Publication


The following have contributed to this page: MD Harriet Stenvall